ライフサイエンスコーパス: nonviral

1 r gene therapy, whether using viral (53%) or nonviral (47%) vectors, have thus far disclosed no evide

2 generality of this approach, we engineered a nonviral, 60-subunit capsid, lumazine synthase from Aqui

3 ays, Th1 cytokine secretion, and by adding a nonviral Ag highly overexpressed in HPV-induced cancers.

4 r gene was 5-10 times higher than the common nonviral agents Fugene-6 and Lipofectamine in the presen

5 very (sonoporation) is a minimally invasive, nonviral and clinically translatable method of gene ther

6 on either in naive mice or in the context of nonviral and viral immunogens.

7 zes cell membranes and offers a nonchemical, nonviral, and noninvasive method for cellular drug deliv

8 s report, we harnessed the highly efficient, nonviral, and plasmid-based piggyBac transposon system t

9 findings suggest a new paradigm of targeting nonviral antigens in immunotherapy of virally associated

10 ystemically in tumor-bearing mice by using a nonviral approach.

11 ct has clear advantages over viral and other nonviral approaches currently being tested.

12 plementing/replenishing miRNAs in vivo using nonviral approaches to boost protective immunity against

13 integration, as well as other site-selective nonviral approaches.

14 ) are up-regulated in PEL and other types of nonviral B-NHL.

15 nsidering that most RNA viruses tolerate few nonviral bases beyond their natural termini.

16 Nonviral, biodegradable polymeric nanoparticles were dev

17 We constructed nonviral biomaterials to transport small nucleic acids t

18 ects the host against development of primary nonviral cancers but also sculpts tumor immunogenicity.

19 gy has been less successful in patients with nonviral cancers owing to their many and varied immune e

20 n engineered variant of lumazine synthase, a nonviral capsid protein with a negatively charged lumina

21 The DNAzyme in complex with a nonviral carrier also significantly inhibited tumor grow

22 er disease due to viral causes (HBV, HCV) or nonviral causes (alcohol-induced liver disease, autoimmu

23 hepatitis C virus infection (HCV), although nonviral causes also play a role in a minority of cases.

24 y HCV, but not against damage due to various nonviral causes.

25 at are compatible with all current viral and nonviral cell delivery methods.

26 e-associated TCRs could be identified in the nonviral chronic liver diseases primary biliary cirrhosi

27 used worldwide as gene vectors (carriers) in nonviral clinical applications of gene delivery, albeit

28 the main cause of cervical cancer, yet other nonviral cofactors are also required for the disease.

29 tent patients and in patients with viral and nonviral coinfections.

30 reover, this pathway also degrades AGO1 in a nonviral context, especially when the production of miRN

31 A promising nonviral delivery method for genetic vaccines involves m

32 Here we show that nonviral delivery of a 9-kb self-amplifying RNA encapsul

33 Alternative emerging strategies for nonviral delivery of CRISPR/Cas9 core components into hu

34 Efficient nonviral delivery of plasmid DNA to rat RPE in vivo was

35 Using a hydrodynamic-based, nonviral delivery protocol, we induced HCV transgene exp

36 nst the EWS-FLI1 gene product by a targeted, nonviral delivery system dramatically inhibits tumor gro

37 The nonviral delivery system uses a cyclodextrin-containing

38 to mammalian cells and may serve as a potent nonviral delivery system.

39 nthetic, self-amplifying mRNA delivered by a nonviral delivery system.

40 Both viral vectors and nonviral delivery systems can be developed to circumvent

41 challenged by the lack of safe and effective nonviral delivery systems for in vivo therapeutic genome

42 fects; and 382 articles describing viral and nonviral delivery systems.

43 liposome (CL)-DNA complexes are a prevalent nonviral delivery vector, but their efficiency requires

44 Our data suggest several viral and nonviral determinants of cervical HPV acquisition and cl

45 Viral and nonviral determinants of HPV acquisition and clearance w

46 unosuppression, the suspected role of MV in "nonviral" diseases such as multiple sclerosis and Paget'

47 cytes can be genetically programmed by using nonviral DNA and turned into powerful antigen-presenting

48 Sleeping Beauty (SB) transposon system is a nonviral DNA delivery system in which a transposase dire

49 oratories are involved in the development of nonviral DNA delivery vehicles.

50 Likewise, foreign nonviral DNA elevates the steady-state level of POLR3E a

51 , we studied whether local gene therapy with nonviral DNA encoding VEGF and/or Ang1 into the ulcer ba

52 cellular transport of hundreds of individual nonviral DNA nanocarriers with 5-nm and 33-ms resolution

53 Nonviral DNA nanoparticles (NPs) can accommodate large g

54 eneimine (PEI) has been used previously as a nonviral DNA transfer vector.

55 A novel method for nonviral DNA transfer, called electron avalanche transfe

56 poly(beta-amino esters) for potential use as nonviral DNA vectors.

57 s in five assays that monitor insertion into nonviral DNA.

58 nanoparticles represent a new and promising nonviral DNA/gene delivery approach endowing immunomodul

59 eract prior viral immunity by priming with a nonviral, DNA vaccine.

60 Nonviral, DNA-mediated gene transfer is an alternative t

61 nct evolutionary origins, in particular from nonviral elements, and insufficient sampling to the spar

62 ct groups of archaeal viruses from different nonviral elements, providing important insights into the

63 budding of CD63 and several other viral and nonviral EMV proteins.

64 In sharp contrast, in nonviral, episomal plasmid DNA-injected mice, transgene

65 ntly larger than that for ESLD patients with nonviral etiologies.

66 with therapeutics for cancers with viral or nonviral etiologies.

67 Specifically, in both virus-associated and nonviral exacerbations, we demonstrate a set of core exa

68 st to squamous cell pathways associated with nonviral exacerbations.

69 e findings imply the potential importance of nonviral factors in natural SIV host species, such as in

70 ected cells with biotinylated DNA encoding a nonviral gene and then infected the cells with wild-type

71 ute the common belief that the efficiency of nonviral gene carriers is dramatically reduced because o

72 ries of pyridinium cationic lipids useful as nonviral gene delivery agents were prepared by reaction

73 th viral gene transfer vectors and transient nonviral gene delivery approaches that are prevalent in

74 Oral nonviral gene delivery is the most attractive and arguab

75 ne approach using ORMOSIL nanoparticles as a nonviral gene delivery platform have a promising future

76 approach for breast cancer, consisting of a nonviral gene delivery system (SN) and a proapoptotic ge

77 es transgene expression in polycation-based, nonviral gene delivery systems, a number of CQ analogues

78 n of all systemically delivered nanoparticle nonviral gene delivery systems.

79 Nonviral gene delivery to the liver has been under evolu

80 ping Beauty (SB) transposon (Tn) system is a nonviral gene delivery tool that has widespread applicat

81 Quantitatively understanding how nonviral gene delivery vectors (polyplexes) are transpor

82 particles are ideal for use as a part of new nonviral gene delivery vectors.

83 These studies might help to develop novel nonviral gene delivery vehicles.

84 extended to biomedical applications, such as nonviral gene delivery, cell targeting and imaging, anti

85 o nondividing cells, is a limiting factor in nonviral gene delivery.

86 important in vivo and for the improvement of nonviral gene delivery.

87 This nonviral gene therapeutic approach led to persistent and

88 support further clinical development of this nonviral gene therapy approach.

89 NA (CL-DNA) complexes are abundantly used in nonviral gene therapy clinical applications.

90 This study demonstrates that a nonviral gene therapy combining the immunological proper

91 ategies for BTICs and establishes a flexible nonviral gene therapy platform with the capacity to chan

92 Nonviral gene therapy represents a promising treatment f

93 the use of small interfering RNA, viral and nonviral gene therapy, and microparticle or viscous gel

94 (bPEI) representing the current standard in nonviral gene therapy.

95 els of glioma, a lethal brain tumor, because nonviral gene transfer is typically transient.

96 Electroporation is one of the most popular nonviral gene transfer methods for embryonic stem cell t

97 the last major barrier to a fully successful nonviral gene transfer system for the liver.

98 Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long-term

99 lls with Sleeping Beauty transposon-mediated nonviral gene transfer, highlighting the potential of th

100 Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that d

101 uman IDO-encoding Sleeping Beauty (SB)-based nonviral gene-integrating approach, halted and attenuate

102 ed in FVIII-knockout (FVIII-KO) mice using a nonviral gene-transfer system.

103 was delivered to donor lungs in vivo using a nonviral gene-transfer vector, polyethylenimine.

104 e findings establish a practical approach to nonviral genetic correction of severe human genetic diso

105 the usefulness of electroporation-enhanced, nonviral genetic immunization for the active immunothera

106 Current nonviral genetic vaccine systems are less effective than

107 FH and in 3 of 22 livers from patients with nonviral hepatic disease.

108 iopsy tissues obtained from individuals with nonviral hepatitis or from normal controls had no prefer

109 atients that is absent in liver tissues from nonviral hepatitis or healthy subjects.

110 ssociation between coffee intake and risk of nonviral hepatitis-related cirrhosis mortality (P for tr

111 rse relationship between caffeine intake and nonviral hepatitis-related cirrhosis mortality became nu

112 onstrates the protective effect of coffee on nonviral hepatitis-related cirrhosis mortality, and prov

113 The 5' ends of the mRNAs contain nonviral heterologous oligonucleotides that originate fr

114 ity achieved by using a lung-tissue-targeted nonviral human IDO gene transfer approach reduced, but d

115 to compare GP73 protein levels in viral and nonviral human liver disease and in normal livers, to id

116 nder cell-free conditions, which supported a nonviral hypothesis for the agent.

117 he strategy of combination of cisplatin with nonviral IL-2 gene therapy resulted in significant antit

118 ant immunity, we discuss analogous viral and nonviral immune concepts and propose working definitions

119 unnoticed in the realm of RNA silencing and nonviral immune responses.

120 tory functions in host immunity to viral and nonviral infections; however, the role of endogenous typ

121 ival was profoundly reduced during different nonviral inflammatory situations in the mouse, through a

122 Our results indicate that expression of a nonviral ITAM-containing protein is sufficient for cell

123 culture media in the laboratory diagnosis of nonviral keratitis.

124 lock TLR2-driven responses to both viral and nonviral ligands at or downstream of the MyD88 adaptor a

125 from patients with chronic HCV infection or nonviral liver disease to analyze markers of Tfh cells.

126 th spontaneous HCV resolution, patients with nonviral liver disease, and normal controls.

127 tients with hepatitis B and C and those with nonviral liver disease.

128 grase may be a simple and effective tool for nonviral long-term gene transfer in the eye.

129 of intron-containing HIV-1 gag RNA and also nonviral luc RNA.

130 /neck cancers, but the mechanisms underlying nonviral malignancies are unclear.

131 Identification of nonviral markers of human immunodeficiency virus (HIV) i

132 Taken together, our findings imply that nonviral maternal factors, such as the cytokine milieu,

133 Thus, SB provides a nonviral means for sustained FVIII gene delivery in a mo

134 The demonstration of a nonviral-mediated delivery of functional proteins into t

135 enesis, which are associated with viral- and nonviral-mediated gene therapy.

136 moderately hydrophobic segments of viral and nonviral membrane fusion proteins that enable these prot

137 we speculate that tetraspanins contribute to nonviral membrane fusions by similar mechanisms.

138 cruitment, since it could be replaced with a nonviral membrane-binding domain without blocking active

139 ted lipofection is a comparatively efficient nonviral method for delivering genes to the corneal endo

140 The Sleeping Beauty (SB) transposon is a nonviral method of gene delivery that overcomes some of

141 A nonviral method of gene delivery was applied to transfec

142 DNA transposons offer an efficient nonviral method of permanently modifying the genomes of

143 om multiple inherited disease patients via a nonviral method.

144 The development of nonviral methods for efficient gene transfer to the lung

145 basis for developing safer, more efficient, nonviral methods for reprogramming human somatic cells.

146 More recently, various nonviral methods that avoid permanent and random transge

147 ansduction has been increasingly replaced by nonviral methods to generate induced pluripotent stem ce

148 iPSC derivation by transfection of a simple, nonviral minicircle DNA construct into human adipose str

149 ry of cardiac progenitor cells (CPCs) with a nonviral minicircle plasmid carrying HIF1 (MC-HIF1) into

150 soenzyme 2 and FIH were inserted into novel, nonviral, minicircle vectors.

151 advances in the mechanisms and strategies of nonviral miRNA delivery systems and provide a perspectiv

152 nistic rationale for the clinical testing of nonviral miRNA mimetics.

153 is report, we demonstrate systemic, in vivo, nonviral mRNA delivery through lipid nanoparticles (LNPs

154 genome into the 3' untranslated region of a nonviral mRNA leads to the specific encapsidation of thi

155 ough N can augment translation initiation of nonviral mRNA, initiation of viral mRNA by N is superior

156 iral RNAs and with our study of encapsidated nonviral mRNAs containing inserts of viral sequence.

157 r effective intracellular delivery, types of nonviral nanomaterials used as delivery vehicles, and th

158 efficiency; therefore it may become a novel nonviral nanosystem for gene delivery.

159 This nonviral, non-stem cell approach enables autologous, adu

160 However, telomere extension by nonviral, nonintegrating methods remains inefficient.

161 RNA.VEGF-A-loaded PLGA NPs are an effective, nonviral, nontoxic, and sustainable form of gene therapy

162 linical implementation of safe and effective nonviral nucleic acid therapeutics, and preparation with

163 vel mouse model for future investigations of nonviral or nonalcoholic causes of HCC development.

164 e augmented by other means in vivo to render nonviral oral gene delivery practical.

165 Single-stranded RNA (ssRNA) molecules of nonviral origin also induce TLR7-dependent production of

166 of viromimetic function in protein cages of nonviral origin has emerged as a strategy to both comple

167 lymphomas and HCCs, but not in lymphomas of nonviral origin or HBV-associated HCC.

168 es the single strand RNA (ssRNA) of viral or nonviral origin.

169 as well as an additional 66 bp insertion of nonviral origin.

170 edge, the first known human -1 PRF signal of nonviral origin.

171 ponses to these LCMV CD4 epitopes as well as nonviral, OVA-specific responses were actively suppresse

172 n be detrimental to the host in a variety of nonviral pathogen infection models.

173 est Nile virus), and 3 had coinfections with nonviral pathogens (2 with Ehrlichia chaffeensis and 1 w

174 nd 2 with varicella zoster virus) and 3 with nonviral pathogens (2 with pneumococcus and 1 with Crypt

175 lso function as antimicrobial agents against nonviral pathogens and directly silence gene targets in

176 by which MPYS mediates host defense against nonviral pathogens are unknown.

177 In contrast, their role in defense against nonviral pathogens is more ambiguous.

178 and demethylation in plant immunity against nonviral pathogens.

179 peripheral blood and was transfected using a nonviral plasmid carrying complementary DNA for modified

180 mphocytes can be genetically programmed with nonviral plasmid DNA for the biogenesis and delivery of

181 noninvasive intravenous administration of a nonviral plasmid formulation.

182 ing Beauty (SB) transposon is an integrative nonviral plasmid system.

183 noninvasive intravenous administration of a nonviral plasmid that is reformulated with gene-targetin

184 the site around the ulcer was injected with nonviral plasmid-encoding full-length complementary DNA

185 ene delivery and increased the efficiency of nonviral platforms to levels previously attained only by

186 l of nature's most efficient DNA viruses and nonviral polyethylenimine/DNA nanocomplexes were reveale

187 cells are often difficult to transfect using nonviral polyplexes.

188 In nonviral preclinical models, the angiogenic cytokine VEG

189 Nonviral producer cell proteins incorporated into retrov

190 that elements of the latency locus protect a nonviral promoter against silencing in primary human cel

191 e cells, including HSCs, and accommodating a nonviral promoter to control the transgene expression in

192 Bacterial encapsulins are a class of nonviral protein cages that self-assemble in vivo into s

193 toward generation of virus-like behavior in nonviral protein cages through rational engineering and

194 positive selection in a variety of viral and nonviral protein-coding genes.

195 expedient means for generating novel mutant nonviral proteins in mammalian cells.

196 Remarkably, nonviral proteins made up about two thirds of VC protein

197 d approach can be applied to other viral and nonviral proteins.

198 proteins between Z and Xenopus Neuralized, a nonviral RING finger protein, indicated that the structu

199 Nonviral risk factors for acquisition of HR HPV infectio

200 Efficient incorporation into BMV virions of nonviral RNA chimeras containing NE and the PE provides

201 er is able to discriminate between viral and nonviral RNA molecules and, interestingly, recognizes an

202 plex that can discriminate between viral and nonviral RNA molecules during the early steps of the enc

203 capable of altering the binding potential of nonviral RNA to levels seen with wild-type vRNAs.

204 o minimize the risk of accidental capping of nonviral RNA when Pol is dormant.

205 s 3' deletion mutants of both vRNA and cRNA, nonviral RNA, and hybrid viral/nonviral RNA, were analyz

206 This region, if placed within nonviral RNA, is capable of altering the binding potenti

207 prevents HBV core protein from assembling on nonviral RNA, preserving the protein for virus productio

208 RNA and cRNA, nonviral RNA, and hybrid viral/nonviral RNA, were analyzed for their ability to interac

209 bility to transform the binding potential of nonviral RNA?

210 st that APOBEC3G interactions with viral and nonviral RNAs that are packaged into viral particles are

211 RNA replication signals, which also directed nonviral RNAs to P bodies.

212 Equivalently sized nonviral RNAs, including high copy potential in vivo com

213 e S-IGR of Lassa virus (LASV) or an entirely nonviral S-IGR-like sequence (Ssyn), are viable, indicat

214 The maintenance of such a nonviral sequence was surprising considering that most R

215 were constructed to contain substitutions of nonviral sequences in place of bases 21 to 72 of the ant

216 We further report that nonviral sequences that are rapidly deleted from recombi

217 t of the ACMV origin of replication flanking nonviral sequences that can be mobilized and replicated

218 e proteins more efficiently than did control nonviral sequences, suggesting that it might be involved

219 es of viral ssRNAs are smaller than those of nonviral sequences.

220 onas vaginalis, which causes the most common nonviral sexually transmitted disease worldwide, is itse

221 and causes trichomonosis, the most prevalent nonviral sexually transmitted disease.

222 chomonas vaginalis is one of the most common nonviral sexually transmitted human infections and, worl

223 richomonas vaginalis (TV) is the most common nonviral sexually transmitted infection (STI) in the wor

224 Trichomoniasis vaginalis is the most common nonviral sexually transmitted infection (STI) worldwide,

225 is estimated to be the most widely prevalent nonviral sexually transmitted infection in the world.

226 Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection worldwide, and i

227 nfective parasite, causes the most prevalent nonviral sexually transmitted infection worldwide.

228 chomonas vaginalis causes the most prevalent nonviral sexually transmitted infection worldwide.

229 ponsible for trichomoniasis, the most common nonviral sexually transmitted infection worldwide.

230 Trichomonas vaginalis is the most prevalent nonviral sexually transmitted infection, affecting an es

231 Trichomoniasis vaginalis, the most prevalent nonviral sexually transmitted infection, is associated w

232 euraminidase repeats that are a signature of nonviral sialidases.

233 , this is the most efficacious and selective nonviral siRNA delivery system for gene silencing in hep

234 or the safety and efficacy of this targeted, nonviral siRNA delivery system.

235 pplicable therapeutic strategy that involves nonviral siRNA delivery to ameliorate the response to va

236 cells (ECs) in vitro and use a rapid 10-min nonviral siRNA transfection technique to determine the e

237 sequence with higher affinity than to other nonviral ssRNA sequences.

238 , we predict the average MLD values of large nonviral ssRNAs scale as N(0.67+/-0.01), where N is the

239 ings indicate that replacement of L-IGR by a nonviral Ssyn could serve as a universal molecular deter

240 These nonviral synthetic IGRs can be used as universal molecul

241 us to generate recombinant LCMVs containing nonviral synthetic IGRs.

242 afe DNA delivery that has great promise as a nonviral system of gene transfer.

243 on, and retroviral integration, we propose a nonviral system that would potentially allow for site-se

244 We have therefore investigated the use of a nonviral system, transferrin-mediated lipofection, to tr

245 of this protein residue in the selection of nonviral target DNA sites is likely to be a general prop

246 rus type 1 integrase, affected the choice of nonviral target DNA sites.

247 for ME panel targets were 100% (195/195) for nonviral targets and 98.0% (192/196) overall.

248 testing algorithm based on repeat testing of nonviral targets avoided 75% (3/4) of false-positive res

249 iteria and a selective testing algorithm for nonviral targets optimizes its utilization, yield, and a

250 s suggest that a comprehensive evaluation of nonviral technologies to deliver self-amplifying RNA vac

251 ds great promise for human gene therapy as a nonviral technology to deliver therapeutic genes.

252 llowing RNA transfection is due, in part, to nonviral terminal sequences present in the in vitro-deri

253 We found that a 2-part nonviral Tet-KRAB inducible expression system repressed

254 Indolent growth was more common in nonviral than viral cirrhosis (50.9% versus 32.1%), part

255 V entry and replication and can be important nonviral therapeutic targets.

256 ctors is a major concern when novel viral or nonviral therapeutics are proposed for applications in h

257 For this reason, they are promising nonviral transfection agents.

258 lated with those needed to achieve efficient nonviral transfection in vivo.

259 Although various nonviral transfection methods are available, cell toxici

260 t retinal pigment epithelium (RPE), by using nonviral transfection methods for gene transfer and the

261 ion of gene expression in central neurons by nonviral transfection techniques, including production o

262 ity of viral vectors and the inefficiency of nonviral transfection techniques.

263 e large research effort focused on enhancing nonviral transfection vectors has clearly demonstrated t

264 t this hypothesis, we have generated using a nonviral transformation procedure a bone marrow-derived

265 Both viral and nonviral tumor antigen-specific T cells resided predomin

266 r directed to the diasialoganglioside GD2, a nonviral tumor-associated antigen expressed by human neu

267 T cells specific for LMP as well as nonviral tumor-associated antigens (epitope spreading) c

268 Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor-associated antigens do not survive long t

269 ct leading to additional T cell responses to nonviral tumor-associated antigens through epitope sprea

270 th most viral vectors, we believe this novel nonviral vector can be of great value for cardiac gene t

271 The SB-Tn system is a promising nonviral vector for efficient genomic insertion conferri

272 modified silica (ORMOSIL) nanoparticles as a nonviral vector for efficient in vivo gene delivery.

273 ganically modified silica nanoparticles as a nonviral vector for gene delivery and biophotonics metho

274 A nonviral vector for highly efficient site-specific integ

275 ansposon (SB-Tn) has emerged as an important nonviral vector for integrating transgenes into mammalia

276 Both viral and nonviral vector gene delivery systems have been used to

277 The improved understanding of what limits nonviral vector gene transfer efficiency in vivo has res

278 To our knowledge, no nonviral vector has been proposed that allows for the po

279 was soon recognized that the properties of a nonviral vector resulting in efficient transfection in v

280 is study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transpo

281 In this study, we develop a novel nonviral vector that robustly and persistently expresses

282 We designed a nonviral vector, PEI-PEG-DUPA (PPD), comprising polyethy

283 prove the efficiency of gene transfer by the nonviral vector.

284 concerns regarding their use in humans make nonviral vectors an attractive alternative.

285 on skipping, to gene therapy using viral and nonviral vectors and cell-based approaches.

286 Consequently, nonviral vectors can incorporate numerous vector composi

287 demonstrations established relatively simple nonviral vectors could mediate gene expression in HepG2

288 Gene transfer using viral or nonviral vectors enables the ability to manipulate speci

289 new understandings in the rational design of nonviral vectors for efficient gene delivery.

290 Such systems have high potential as nonviral vectors for gene delivery and will allow for mo

291 biochemical mechanisms associated with using nonviral vectors for gene delivery.

292 Research into the design of suitable nonviral vectors has been slow.

293 Gene therapy based on delivery of viral and nonviral vectors has shown great promise for the treatme

294 hough physical approaches, viruses, and some nonviral vectors have been employed for CRISPR/Cas9 deli

295 e advantages, gene-delivery strategies using nonviral vectors have poorly translated into clinical su

296 Nonviral vectors, on the other hand, offer safety but ha

297 Among the nonviral vectors, the lipoplexes (complexes of cationic

298 molecules, utilizing a variety of viral and nonviral vectors, to induce antigen-specific immune resp

299 delivery are usually classified as viral and nonviral vectors.

300 This article reviews both viral and nonviral work with focus on two candidates for clinical